P A Tang1, A E Hay2, C J O'Callaghan2, N Mittmann3, C R Chambers1, J L Pater2, N B Leighl4. 1. Tom Baker Cancer Centre, University of Calgary, Calgary, AB; 2. ncic Clinical Trials Group, Kingston, ON; 3. ncic Clinical Trials Group, Kingston, ON;; Health Outcomes and Pharmacoeconomic (hope) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON; 4. Princess Margaret Cancer Centre, Toronto, ON.
Abstract
BACKGROUND: Cost avoidance occurs when, because of provision of a drug therapy [drug cost avoidance (dca)] or a pathology test [pathology cost avoidance (pca)] during trial participation, health care payers need not pay for standard treatments or testing. The aim of our study was to estimate the total dca and pca for Canadian patients enrolled in relevant phase iii trials conducted by the ncic Clinical Trials Group. METHODS: Phase iii trials that had completed accrual and resulted in dca or pca were identified. The pca was calculated based on the number of patients screened and the test cost. The dca was estimated based on patients randomized, the protocol dosing regimen, drug cost, median dose intensity, and median duration of therapy. Costs are presented in Canadian dollars. No adjustment was made for inflation. RESULTS: From 1999 to 2011, 4 trials (1479 patients) resulted in pca and 17 trials (3195 patients) resulted in dca. The total pca was estimated at $4,194,849, which included testing for KRAS ($141,058), microsatellite instability ($18,600), and 21-gene recurrence score ($4,035,191). The total dca was estimated at $27,952,512, of which targeted therapy constituted 43% (five trials). The combined pca and dca was $32,147,361. CONCLUSIONS: Over the study period, trials conducted by the ncic Clinical Trials Group resulted in total cost avoidance (pca and dca) of approximately $7,518 per patient. Although not all trials lead to cost avoidance, such savings should be taken account when the financial impact of conducting clinical research is being considered.
BACKGROUND: Cost avoidance occurs when, because of provision of a drug therapy [drug cost avoidance (dca)] or a pathology test [pathology cost avoidance (pca)] during trial participation, health care payers need not pay for standard treatments or testing. The aim of our study was to estimate the total dca and pca for Canadian patients enrolled in relevant phase iii trials conducted by the ncic Clinical Trials Group. METHODS: Phase iii trials that had completed accrual and resulted in dca or pca were identified. The pca was calculated based on the number of patients screened and the test cost. The dca was estimated based on patients randomized, the protocol dosing regimen, drug cost, median dose intensity, and median duration of therapy. Costs are presented in Canadian dollars. No adjustment was made for inflation. RESULTS: From 1999 to 2011, 4 trials (1479 patients) resulted in pca and 17 trials (3195 patients) resulted in dca. The total pca was estimated at $4,194,849, which included testing for KRAS ($141,058), microsatellite instability ($18,600), and 21-gene recurrence score ($4,035,191). The total dca was estimated at $27,952,512, of which targeted therapy constituted 43% (five trials). The combined pca and dca was $32,147,361. CONCLUSIONS: Over the study period, trials conducted by the ncic Clinical Trials Group resulted in total cost avoidance (pca and dca) of approximately $7,518 per patient. Although not all trials lead to cost avoidance, such savings should be taken account when the financial impact of conducting clinical research is being considered.
Authors: Doreen A Ezeife; Tony H Truong; Daniel Y C Heng; Sylvie Bourque; Stephen A Welch; Patricia A Tang Journal: Cancer Date: 2015-01-20 Impact factor: 6.860
Authors: Paul J Martin; Nancy Davenport-Ennis; Nicholas J Petrelli; F Marc Stewart; Frederick R Appelbaum; Al Benson Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Hsien-Yeang Seow; Patrick Whelan; Mark N Levine; Kathryn Cowan; Barbara Lysakowski; Brenda Kowaleski; Anne Snider; Rebecca Y Xu; Andrew Arnold Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Lillian L Siu; Jeremy D Shapiro; Derek J Jonker; Chris S Karapetis; John R Zalcberg; John Simes; Felix Couture; Malcolm J Moore; Timothy J Price; Jehan Siddiqui; Louise M Nott; Danielle Charpentier; Winston Liauw; Michael B Sawyer; Michael Jefford; Nadine M Magoski; Andrew Haydon; Ian Walters; Jolie Ringash; Dongsheng Tu; Chris J O'Callaghan Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: E Liniker; M Harrison; J M J Weaver; N Agrawal; A Chhabra; V Kingshott; S Bailey; T G G Eisen; P G Corrie Journal: Br J Cancer Date: 2013-09-24 Impact factor: 7.640
Authors: Sebastián García-Sánchez; Roberto Collado-Borrell; Eva González-Haba; José Luis Revuelta-Herrero; Vicente Escudero-Vilaplana; María Belén Marzal-Alfaro; María Norberta Sánchez-Fresneda; Ana Mur-Mur; Ana Herranz; Miguel Martín; María Sanjurjo Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738
Authors: Domingo Antonio Sánchez Martínez; Federico Salas-Lucia; Hanzi Jiang; Paula Ruiz-Carreño; José Luis Alonso Romero Journal: BMC Health Serv Res Date: 2022-07-26 Impact factor: 2.908